Huntington’s disease: pathomechanism and therapeutic perspectives

@article{Grdin2004HuntingtonsDP,
  title={Huntington’s disease: pathomechanism and therapeutic perspectives},
  author={G. G{\'a}rdi{\'a}n and L. V{\'e}csei},
  journal={Journal of Neural Transmission},
  year={2004},
  volume={111},
  pages={1485-1494}
}
Summary.Huntington’s disease is an autosomal dominantly inherited progressive neurodegenerative disorder. The mutant gene has been localised to chromosome 4p16.3. The gene product huntingtin is widely distributed in both neurones and extraneuronal tissues. The mutation in Huntington’s disease involves the expansion of a trinucleotide (CAG) repeat encoding glutamine. The etiology of Huntington’s disease is yet unknown but increasing evidence suggests important role of altered gene transcription… Expand
Molecular mechanisms and potential therapeutical targets in Huntington's disease.
Huntington's disease look-alikes.
Huntington’s Disease: An Update
Animal models of Huntington's disease.
Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.
Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 65 REFERENCES
Transgenic models of Huntington's disease.
Molecular genetics of Huntington's disease.
Scientific approaches to Huntington's disease.
Minocycline and doxycycline are not beneficial in a model of Huntington's disease
Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease
  • E. Hockly, V. Richon, +13 authors G. Bates
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2003
Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates.
...
1
2
3
4
5
...